Rocket Pharmaceuticals (RCKT) Net Cash Flow (2014 - 2026)

Rocket Pharmaceuticals has disclosed Net Cash Flow across 13 years of filings, most recently posting -$27.9 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$27.9 million, up 75.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$221000.0 (down 101.52% YoY), and the FY2025 annual result was -$86.1 million, down 179.93% from the prior year.
• Net Cash Flow came in at -$27.9 million for Q1 2026 at Rocket Pharmaceuticals, down from $1.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $180.6 million in Q3 2023 to a low of -$169.8 million in Q4 2023.
• The 5-year median for Net Cash Flow is -$17.0 million (2025), against an average of -$10.8 million.
• Across the five-year window, Net Cash Flow surged 1877.56% in 2023 and sank 610.0% in 2025, its largest moves.
• Rocket Pharmaceuticals' Net Cash Flow stood at -$56.2 million in 2022, then plunged by 202.23% to -$169.8 million in 2023, then soared by 157.75% to $98.0 million in 2024, then slumped by 98.38% to $1.6 million in 2025, then sank by 1863.22% to -$27.9 million in 2026.
• The last three Net Cash Flow figures came in at -$27.9 million (Q1 2026), $1.6 million (Q4 2025), and $43.1 million (Q3 2025), per Business Quant data.